Seretide Evohaler fluticasone propionate 250mcg + salmeterol xinafoate 25mcg per actuation

2 trials

Sponsors

Prosonix Limited

Conditions

Healthy subjects, intended disorder is asthmaRespiratory Healthy subjects, intended disorder is asthma

Early Phase 1

Systemic exposure bioequivalence study between two formulations of orally inhaled fluticasone propionate and salmeterol xinafoate

Active, not recruitingPACTR201507001200173

Prosonix LimitedHealthy subjects, intended disorder is asthma

Start: 2015-08-14Target: 120Updated: 2026-09-14

Unknown Phase

Systemic exposure bioequivalence study between two formulations of orally inhaled fluticasone propionate and salmeterol xinafoate....

Active, not recruitingPACTR201508001220273

Prosonix LimitedRespiratory Healthy subjects, intended disorder is asthma

Start: 2015-08-28Target: 60Updated: 2026-09-14